9,154 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. acquired a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,154 shares of the company’s stock, valued at approximately $34,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC bought a new position in Kyverna Therapeutics in the third quarter worth approximately $33,000. Creative Planning bought a new stake in Kyverna Therapeutics during the 3rd quarter valued at $54,000. Jacobs Levy Equity Management Inc. bought a new stake in Kyverna Therapeutics during the 3rd quarter valued at $97,000. BNP Paribas Financial Markets boosted its position in Kyverna Therapeutics by 2,166.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after acquiring an additional 25,997 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Kyverna Therapeutics during the 3rd quarter valued at $169,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Performance

NASDAQ:KYTX opened at $3.07 on Wednesday. Kyverna Therapeutics, Inc. has a 52 week low of $3.02 and a 52 week high of $35.06. The stock’s 50-day moving average price is $4.00 and its 200-day moving average price is $5.48.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. As a group, equities research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KYTX. UBS Group started coverage on Kyverna Therapeutics in a research report on Thursday, October 10th. They set a “buy” rating and a $13.00 target price on the stock. Wells Fargo & Company decreased their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, November 15th. HC Wainwright decreased their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Rodman & Renshaw began coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.